Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Additional Reading from MarketBeat Media 3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026Author: Chris Markoch. First Published: 1/20/2026. 
Key Points - Eli Lilly leads the GLP-1 market while advancing late-stage drugs in Alzheimer’s, oncology, and cardiovascular disease.
- Viking Therapeutics offers a high-upside GLP-1 challenger supported by strong trial data and institutional ownership.
- Biogen provides exposure to neurodegenerative disease breakthroughs at a valuation below its historical averages.
The words “sure-fire” and biotechnology stocks rarely go together. The biotechnology sector carries higher-than-average risk: success often hinges on clinical trial outcomes, regulatory decisions, and the ability to commercialize therapies at scale. Even promising programs can fail or face delays. Still, it only takes a single FDA approval to generate outsized returns. Many biotechs begin as low-priced stocks, so finding a winner can feel like buying a lottery ticket—one reason investors continue to hunt for opportunities in this space. Some analysts are revisiting historical monetary resets and the role gold has played when governments faced large debt imbalances.
A new free report examines how gold was previously revalued to support national balance sheets, why recent comments from policymakers and investors have renewed interest in this topic, and what individuals may want to understand about protecting long-term savings during periods of monetary change. Download the free report here At first glance, the three names below may seem conservative for growth investors. But each has clear catalysts that could produce significant upside in 2026. Eli Lilly: The Large-Cap Anchor With More Growth to Come The first name on this list is Eli Lilly & Co. (NYSE: LLY). Lilly is the leader in the fast-growing GLP-1 market, putting it at the center of two massive drug markets: obesity and diabetes. Zepbound and Mounjaro alone justify Lilly's inclusion. Demand for GLP-1 therapies continues to exceed supply, and obesity treatments are typically long-term therapies rather than one-time fads, which should expand Lilly's total addressable market (TAM). If you want exposure to one of the biggest medical trends of the decade, LLY is hard to ignore. Adding to the bull case are Lilly's late-stage candidates in Alzheimer's, oncology, and cardiovascular disease. Those programs could provide additional growth drivers beyond GLP-1s. LLY stock traded for over $1,000 a share as of Jan. 16—a level that may be out of reach for many investors. Even so, with a price-to-earnings (P/E) ratio around 50x, Lilly has historically commanded even higher valuations. Analysts forecast more than 32% earnings growth this year, which could support further appreciation in the share price if the company meets expectations. Viking Therapeutics: A Mid-Cap Stock That Could Be a Worthy Challenger If LLY feels too expensive, Viking Therapeutics Inc. (NASDAQ: VKTX) offers a lower-cost way to play the GLP-1 opportunity. Viking has both oral and injectable GLP-1 candidates in late-stage trials, and early data have shown notable weight-loss results. Two points can be true at once: Lilly remains the dominant player, but the market needs competitors, and Viking could be one of them. If Viking's programs clear clinical and regulatory hurdles, the company could become an attractive acquisition target. Analysts have a consensus price target of $87.14 on VKTX stock, implying roughly a 155% increase from its closing price on Jan. 16. That optimism is supported by institutional ownership above 70%, suggesting significant interest from professional investors. Biogen: May Be on the Brink of Breakthroughs for High-Impact Diseases Beyond the GLP-1 trend, many investors are searching for the next major therapeutic breakthrough. Treatments for Alzheimer's and other neurodegenerative diseases represent one of the largest unmet medical needs today. Biogen Inc. (NASDAQ: BIIB) is a direct way to gain exposure to that opportunity. The company has multiple neurodegenerative candidates in its pipeline, and a single successful program could produce substantial returns for shareholders. BIIB stock is up about 16% over the past 12 months, driven in part by a roughly 14% gain in the three months ending Jan. 16. Analysts see further upside, with a consensus price target of $190.50, roughly 15% above the current level. At about 10x forward earnings, Biogen also appears reasonably valued for the year ahead. All three names offer different risk-reward profiles: Lilly provides large-cap exposure to a proven megatrend, Viking is a mid-cap growth option with takeover potential if trials succeed, and Biogen offers speculative upside tied to high-impact neurodegenerative programs. As always with biotech, risks are material. Clinical setbacks, regulatory delays, or competitive pressures can quickly change the outlook. Investors should do their own research, consider position sizing carefully, and diversify to manage the inherent volatility in this sector.
|
Post a Comment
Post a Comment